Market Overview

Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy

Related CGEN
Compugen Names Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program IND filing For COM701 Anticipated in 2017
Compugen Achieves Milestone Event With Bayer

Compugen Ltd. (NASDAQ: CGEN), announced today the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy. These new candidates have been shown to be expressed in multiple types of tumors and were shown to have an immunomodulatory activity in affecting both innate and adaptive immune responses, thus providing the potential for an efficient and targeted approach in cancer treatment. By offering a different mode of action from Compugen's other immune checkpoint candidates, these molecules further broaden the scope of the Company's Pipeline Program for monoclonal antibody treatment of cancer.

Posted-In: News FDA


Related Articles (CGEN)

View Comments and Join the Discussion!